Krsnaa DiagnosticsQ3 FY24

Krsnaa Diagnostics Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹518.7P/E: 16.7Market Cap: ₹1.7K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

No

Order

Yes

Capex

Yes

2 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 2
  • Krsnaa Diagnostics expects a revenue growth CAGR of around 30% for FY '25, continuing the current growth trajectory.
  • Expansion into more states and large projects such as Assam, Odisha, Rajasthan, and Maharashtra underpin this growth.
  • New projects and tenders will add to gross block and incremental revenues as centers get implemented and mature.
  • The company is becoming selective in tender participation, focusing on those aligned with financial metrics.
  • B2C vertical is in early stages but expected to grow as brand acceptance and package sales increase.
  • Rajasthan tender's revenue meaningful contribution expected in the second half or Q4 of FY '25 after court decision and lab installations.
  • Increasing volume is a key growth driver, particularly given the PPP model which offers significant patient volumes.
  • The test mix is expected to remain around 60-65% radiology and 35-40% pathology, with a target to approach a 50-50 mix.

See what Krsnaa Diagnostics management said on margin guidance — free account, 30 seconds.

Fundraise plans

No
  • Krsnaa Diagnostics aims to remain largely debt-free, relying primarily on internal accruals and vendor credit for funding.
  • Debt may be considered if it proves to be a more efficient financing option for specific projects.
  • Discussions are underway to adopt an asset-light pay-per-use model for equipment, reducing upfront capex needs.
  • For upcoming capex, including potential Rajasthan tender-related investments, a combination of internal funds, vendor credit, and possible debt will be utilized.
  • No explicit mention of raising funds through equity is noted in the provided transcript.
  • The company emphasizes minimizing debt and maintaining a strong balance sheet while pursuing growth opportunities.

See what Krsnaa Diagnostics management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Planned capex for FY '25 (2024-25) is INR150-200 crores, excluding Rajasthan tender.
  • Rajasthan tender capex, if won, is an additional INR200-250 crores, potentially raising total capex to INR450-500 crores over approximately one year.
  • Capex mainly towards installing large, capex-heavy equipment such as analyzers and immunoassay machines.
  • Exploring asset-light strategies including pay-per-use or lease models for equipment to reduce outright purchases.
  • Capex funding through a mix of internal accruals, vendor financing, and possible debt if efficient, though company aims to remain largely debt-free.
  • New projects like Maharashtra MRI/CT and other state tenders will require incremental capex within the stated range.
  • Focus remains on selective tender participation aligned with financial metrics to optimize return on capital employed (ROCE).

Track Krsnaa Diagnostics — get its next earnings analysis in your feed

How does Krsnaa Diagnostics rank vs peers in Healthcare Services?

Pro feature
ThisKrsnaa Diagnostics
Rev 2Mar 3

How does Krsnaa Diagnostics rank in Healthcare Services?

Compare Krsnaa Diagnostics against every Healthcare Services company (Q3 FY24) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

Others in Healthcare Services this season

  • Chandan Healthca (Q2 FY27)

    Q2 FY27 operating income: ₹57.94 Cr, up 45.04% YoY from ₹39.95 Cr (Page 8) . Key investor presentation takeaways from Chandan Healthcare Ltd's Q2 FY27 investor

  • Invicta Diagnostic (Q2 FY27)

    Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4). Key results statement takeaways from Invicta Diagnostic Ltd's Q2 FY2

  • Unihealth Hosp (Q2 FY27)

    1,270 million with a year-on-year (YoY) growth of 6.3% . Key results statement takeaways from Unihealth Hospitals Ltd's Q2 FY27 results statement — and how it r

  • Sangani Hospital (Q2 FY27)

    1008.56 lakhs (~11.8% increase). Key results statement takeaways from Sangani Hospitals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →